Education
About Us
Working with TipRanks
Follow Us
Kenvue, Inc. (KVUE)
NYSE:KVUE
KVUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.47 - $25.17
Previous CloseN/A
Volume2.33M
Average Volume (3M)35.82M
Market Cap
$30.11B
Enterprise Value$47.93B
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$8.74B
Price to Earnings (P/E)21.3
Beta0.28
Next Earnings
Oct 23, 2025EPS Estimate
0.26Last Dividend Ex-Date
Aug 13, 2025Dividend Yield5.07%
Share Statistics
EPS (TTM)0.29
Shares Outstanding1,919,070,000
10 Day Avg. Volume43,969,963
30 Day Avg. Volume35,822,128
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)4.20
Price to Sales (P/S)2.62
P/FCF Ratio30.38
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit5.46
Enterprise Value/Ebitda15.78
Forecast
1Y Price Target
$20.38Price Target Upside25.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Dividend And ValuationSupporters of KVUE valuation include the shares’ 5% dividend and potential SG&A efficiencies.
Legal RiskKVUE's financial risk still remains limited, as the risk is mainly centered around public perception, in our view (vs. legal risk from the lawsuit that was struck down).
Scientific EvidenceKVUE has reiterated its stance that there is no scientific evidence that acetaminophen causes autism, a position supported by independent public health and medical professionals.
Bears Say
FDA ActionsThe FDA will be initiating the process to change the safety label on acetaminophen, based on studies suggesting a potential link between its use and an increased risk of neurological conditions such as autism.
Market ReactionKVUE stock was down nearly -20% at one point on the news before closing the day down around -9%.
Public PerceptionThe largest risk is around public opinion which is mixed, and even if it leans toward the side of Tylenol being unsafe for pregnant women, this is a small cohort of consumers using the product.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $15.47 and its highest was $25.17 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $30.11B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Oct 23, 2025 which is in 15 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Jul 14, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.282 by $0.008.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.207 which represents an annual dividend yield of 5.07%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.26.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,919,070,000 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.282. Following the earnings report the stock price went up 2.223%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
Kenvue, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.38 (25.65% Upside)
$20.38 (25.65% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 32.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 29.1%
Last 30 Days ▲ 29.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.47%
12-Months-Change
Fundamentals
Return on Equity
13.56%
Trailing 12-Months
Asset Growth
2.61%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue, Inc. (KVUE) is a prominent player in the consumer health industry, specializing in the development, production, and marketing of a diverse range of health and wellness products. The company operates across several sectors, including over-the-counter medications, skincare, and other personal care products. Kenvue is committed to enhancing consumer health by providing innovative and reliable solutions that cater to the evolving needs of its global customer base.
KVUE Revenue Breakdown
42.23% Self Care
30.33% Essential Health
27.43% Skin Health and Beauty
KVUE Stock 12 Month Forecast
Average Price Target
$20.38
▲(25.65% Upside)
Technical Analysis
Ownership Overview
1.13% Insiders
33.69% Mutual Funds
17.41% Other Institutional Investors
19.21% Public Companies and Individual Investors